Clinical Trial Update: Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating monoclonal antibody therapy for myelodysplastic syndromes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Monoclonal antibody therapy (unspecified)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: WITHDRAWN